Peginterferon Alfa-2B is used alone or in combination with ribavirin (a medicine) to treat chronic (long-term) hepatitis C infection (liver swelling caused by a virus) in persons who have already been treated with interferon-alpha (a medication comparable to peginterferon alfa-2b). Interferons are a type of drug that includes peginterferon alfa-2b. Peginterferon alpha-2b is a mixture of interferon and polyethylene glycol that allows interferon to stay active in your body for longer. Peginterferon alpha-2b acts by lowering hepatitis C virus (HCV) levels in the body. Peginterferon Alfa-2B may not treat hepatitis C or protect you from hepatitis C consequences including cirrhosis (liver scarring), liver failure, or liver cancer. Peginterferon Alfa-2B may not be effective in preventing hepatitis C from spreading to others. Peginterferon Alfa-2B is a type of recombinant interferon used in combination therapy to treat chronic Hepatitis C, a liver infection caused by the Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus with nine genotypes, the most prevalent of which is genotype 1, which affects 72 percent of all chronic HCV patients in the United States. Since 2011, the discovery of Direct Acting Antivirals (DAAs) has resulted in less use of Peginterferon Alfa-2B as a treatment option for chronic Hepatitis C. The alfa-2b moiety of recombinant human interferon is used to make peginterferon alfa-2b, which binds to human type 1 interferon receptors. The Janus kinase/signal transducer and activator of transcription (JAK/STAT) pathway are activated when this receptor is activated and dimerized, which triggers the body's innate antiviral response. Peginterferon Alfa-2B use has been linked to several serious side effects, including the worsening and development of endocrine and immunological disorders, retinopathies, cardiovascular and neuropsychiatric problems, and an increased risk of cirrhosis-related hepatic decompensation. Since the development of newer interferon-free antiviral medicines, the use of Peginterferon Alfa-2B has decreased significantly. Peginterferon Alfa-2B is an injectable medication with a variable dose (tradename Pegintron) that is used to treat chronic Hepatitis C. Pegintron was approved by the FDA in 2001 for the treatment of HCV with Ribavirin or other antiviral medications. Peginterferon Alfa-2B and Ribavirin, when used together, have been observed to produce an SVR of 41% for genotype 1 and 75% for genotypes 2-6 after 48 weeks of treatment. In conjunction with Ribavirin and an NS3/4A protease inhibitor for genotype 1 or without an NS3/4A protease inhibitor for genotypes 2-6, Peginterferon Alfa-2B is suggested for the treatment of HCV. In patients with contraindications to or considerable intolerance to other antiviral medications, it may be given as a monotherapy. Peginterferon Alfa-2B reduces viral replication, lowers cell proliferation, promotes apoptosis, and has anti-angiogenic properties in infected cells. Increases macrophage phagocytic activity, activates NK cells, stimulates cytotoxic T-lymphocytes, and upregulates the Th1 T-helper cell subset, among other immunomodulatory actions. Also increases serum neopterin and 2'5' oligoadenylate synthetase concentrations, enhances body warmth and causes reversible reductions in leukocyte and platelet counts.

Peginterferon alpha-2b acts by lowering hepatitis C virus (HCV) levels in the body. Peginterferon Alfa-2B may not treat hepatitis C or protect you from hepatitis C consequences including cirrhosis (liver scarring), liver failure, or liver cancer.

An online search for the wholesale price for sale of Peginterferon Alfa-2B for distributors will reveal a wide range of costs. It will vary from store to store depending on your visit and the country of the wholesale market.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Peginterferon Alfa-2B distributors offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these substance manufacturers and this substance Peginterferon Alfa-2B suppliers that you are looking for. These also enable you to check the dossier status of this medicine and the GMP approvals of the different variants of Peginterferon Alfa-2B. Also, each manufacturer or supplier product description contains essential information about this substance including clinical data, stability zones, countries where Peginterferon Alfa-2B is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over these medicine offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical product deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and order process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers Peginterferon Alfa-2B suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that this medicine manufacturers list has, we qualify their companies before they are onboarded on the platform. This allows us to screen Peginterferon Alfa-2B Manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.